Cargando…
P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431233/ http://dx.doi.org/10.1097/01.HS9.0000846984.81563.96 |
| _version_ | 1784779996395470848 |
|---|---|
| author | Gupta, V. Mascarenhas, J. Kremyanskaya, M. Rampal, R. K. Talpaz, M. Kiladjian, J.-J. Vannucchi, A. Verstovsek, S. Colak, G. Dey, D. Harrison, C. |
| author_facet | Gupta, V. Mascarenhas, J. Kremyanskaya, M. Rampal, R. K. Talpaz, M. Kiladjian, J.-J. Vannucchi, A. Verstovsek, S. Colak, G. Dey, D. Harrison, C. |
| author_sort | Gupta, V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431233 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94312332022-08-31 P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS Gupta, V. Mascarenhas, J. Kremyanskaya, M. Rampal, R. K. Talpaz, M. Kiladjian, J.-J. Vannucchi, A. Verstovsek, S. Colak, G. Dey, D. Harrison, C. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431233/ http://dx.doi.org/10.1097/01.HS9.0000846984.81563.96 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Gupta, V. Mascarenhas, J. Kremyanskaya, M. Rampal, R. K. Talpaz, M. Kiladjian, J.-J. Vannucchi, A. Verstovsek, S. Colak, G. Dey, D. Harrison, C. P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title | P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title_full | P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title_fullStr | P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title_full_unstemmed | P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title_short | P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| title_sort | p1029: matching-adjusted indirect comparison (maic) of pelabresib (cpi-0610) in combination with ruxolitinib vs ruxolitinib or fedratinib monotherapy in patients with intermediate or high-risk myelofibrosis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431233/ http://dx.doi.org/10.1097/01.HS9.0000846984.81563.96 |
| work_keys_str_mv | AT guptav p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT mascarenhasj p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT kremyanskayam p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT rampalrk p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT talpazm p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT kiladjianjj p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT vannucchia p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT verstovseks p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT colakg p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT deyd p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis AT harrisonc p1029matchingadjustedindirectcomparisonmaicofpelabresibcpi0610incombinationwithruxolitinibvsruxolitiniborfedratinibmonotherapyinpatientswithintermediateorhighriskmyelofibrosis |